IceCure Medical Ltd (NASDAQ:ICCM) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET
Company Participants
Eyal Shamir – Chief Executive Officer
Ronen Tsimerman – Chief Financial Officer
Kenneth Tomkovich – Co-Primary Investigator
Conference Call Participants
Ben Haynor – Alliance Global Partners
Kemp Dolliver – Brookline Capital Markets
Operator
Welcome to IceCure’s Conference Call on the Financial Results for the First Half of 2022. Management will provide an overview of IceCure’s financial results as well as clinical, commercial, and operational highlights.
Participating on the call today are IceCure’s CEO, Eyal Shamir; and CFO, Ronen Tsimerman. They are joined today by Dr. Kenneth Tomkovich, the Co-Primary Investigator for IceCure’s ICE3 ProSense clinical trial on cryoablation of small, low-risk breast cancer. Following the presentation, IceCure’s management and Dr. Tomkovich will be available for a question-and-answer session.
Before we begin, I will now take a moment to read the statement about forward-looking statements. This call and the question-and-answer session that follows, it contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.
Words such as expects, anticipates, intends, plans, believes, seeks, estimates, and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward-looking statement in this presentation when it discusses pursuit of regulatory approvals and various jurisdictions, strategic plans, commercial growth, expansion of clinical applications and potential market adoption of its minimally-invasive cryoablation technology, advancing regulatory and commercial strategies and expected quarter-over-quarter revenue variations and other key business highlights for future periods.
Because such statements deal with future events and are based on IceCure’s current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this presentation.
The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 1, 2022, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
I will now turn the call over to IceCure’s CEO, Eyal Shamir.